Susan Galbraith

Susan Galbraith

Executive Vice-President, Oncology R&D, AstraZeneca

Susan Galbraith was appointed as Executive Vice-President, Oncology R&D in July 2021. In this role, Susan has global accountability for the Oncology portfolio from discovery through to late-stage development. Since joining AstraZeneca in 2010, Susan has been instrumental in bringing seven new medicines to patients, four of which are now blockbusters. Prior to AstraZeneca, Susan held senior Oncology R&D roles at Bristol-Myers Squibb. A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. She holds an honorary Doctorate of Medical Science from the Institute of Cancer Research and is a Fellow of the Academy of Medical Sciences.┬áSusan serves on the American Association for Cancer Research Board of Directors, the Institute of Cancer Research Scientific Advisory Board and the European Association of Cancer Research Advisory Council; she is also the current Chair of the Board at Definiens AG.